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Hospitalizations and Costs Incurred at the Facility Level after Scale-up of Malaria Control:
Pre-Post Comparisons from Two Hospitals in Zambia
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Nancy Nachbar, Yann Derriennic, Stephen Musau, Petan Hamazakaza, Khozya D. Zyambo,
Nancy M. Zyongwe, Busiku Hamainza, and Philip E. Thuma
Abt Associates, Cambridge, Massachusetts; Clinical Research Department, Macha Research Trust, Choma, Zambia; Johns Hopkins Malaria
Research Institute, Malaria Research Department, Macha Research Trust, Choma, Zambia; Abt Associates, Bethesda, Maryland;
President’s Malaria Initiative, Bureau of Global Health, United States Agency of International Development, Washington,
District of Columbia; Farming Systems and Social Sciences, Zambia Agricultural Research Institute, Kabwe, Zambia;
Department of Paediatric and Child Health, Livingstone General Hospital, Livingstone, Zambia; Southern Province
Medical Office, Zambia Integrated Systems Strengthening Programme, Abt Associates, Livingstone, Zambia;
National Malaria Control Center, Lusaka, Zambia

Abstract. There is little evidence on the impact of malaria control on the health system, particularly at the facility
level. Using retrospective, longitudinal facility-level and patient record data from two hospitals in Zambia, we report a
pre-post comparison of hospital admissions and outpatient visits for malaria and estimated costs incurred for malaria
admissions before and after malaria control scale-up. The results show a substantial reduction in inpatient admissions
and outpatient visits for malaria at both hospitals after the scale-up, and malaria cases accounted for a smaller
proportion of total hospital visits over time. Hospital spending on malaria admissions also decreased. In one hospital,
malaria accounted for 11% of total hospital spending before large-scale malaria control compared with < 1% after
malaria control. The findings demonstrate that facility-level resources are freed up as malaria is controlled, potentially
making these resources available for other diseases and conditions.

use of services and costs incurred. Various studies find that
malaria inpatient admissions decrease with better malaria
control strategies, but study results differ regarding the
concurrent effect on admissions for other diseases.4–7 Other
studies have provided cost estimates for treating severe
versus uncomplicated malaria cases, or assessed the cost
effectiveness or cost savings at the health facility from a
particular malaria control intervention.8–11
The purpose of this study was to assess how the implementation and scale-up of malaria control in the catchment
area affects the health system by focusing specifically at the
hospital level. We compare the number of inpatient admissions and outpatient visits for malaria during the pre-post
period when malaria control interventions were scaled up
in the relevant catchment areas. We also looked at how
the proportion of inpatient admissions for malaria relative to
admissions for other diseases changes over this period. Finally,
we estimate the total yearly costs incurred at the facility level
for treating malaria admissions during the pre-post period and
assess how the proportion of costs for malaria admission relative to total hospital expenditures changes over time. Unlike
other studies that have focused specifically on malaria control
and its relationship with inpatient admissions, or its effect
on the costs incurred at the facility, this study ties these different components together to provide a more comprehensive understanding of how malaria control affects the health
facility in terms of admissions and costs.

INTRODUCTION
According to the most recent estimates from the World
Health Organization World Malaria Report 2012, malaria
accounted for approximately 660,000 deaths in 2010, of
which almost 86% were among children < 5 years of age.1
Most malaria deaths (91%) and cases occur in Africa.1 Significant improvements have been made over the past decade
in reducing the incidence of malaria. Of the 99 countries with
ongoing malaria transmission, 50 of these countries are on
track to reduce the incidence of reported malaria cases by
75% by 2015.1 Globally, over the past decade, malaria incidence has decreased by 17% and malaria-specific mortality
rates have decreased by 26%.2
The principal malaria control interventions include vector
control strategies, namely the distribution of long-lasting
insecticide-treated nets and the application of indoor residual spraying (IRS), as well as increased use of rapid diagnostic tests (RDTs), first-line treatment of uncomplicated
Plasmodium falciparum malaria with artemisinin-based combination therapy (ACT), and intermittent preventive treatment of malaria for pregnant women. Zambia, where this
study was conducted, is a country in southern Africa with a
high prevalence of malaria. Zambia was an early adopter
of effective malaria control interventions, including ACTs
as a first-line treatment, free RDTs, mass distribution of
insecticide-treated nets (ITNs), and wide deployment of
targeted IRS.2,3
Compared with evidence on the effect of malaria control
on mortality and morbidity outcomes, there is less evidence
about the broader impact of malaria control on the health
system, particularly at the service delivery level in terms of

BACKGROUND
Study areas and facility selection. Our study sites include
two hospitals in the Southern Province of Zambia. These
hospitals were selected because data were available during
the period before significant scale-up of malaria control,
thus enabling a pre-post comparison of malaria admissions
and hospital costs.

*Address correspondence to Alison B. Comfort, Abt Associates,
55 Wheeler St., Cambridge, MA 02138. E-mail: alison_comfort@
abtassoc.com
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The first hospital, Macha Mission Hospital (MMH), is
a church-administered hospital located in rural Choma
District. It has been involved in malaria research for more
than 20 years and is currently the site for the Macha
Research Trust, the successor to the independent Malaria
Institute at Macha (MIAM), which was officially opened in
2005. This hospital has 208 beds and is the referral hospital
for 13 rural health centers (RHCs) located in Choma and
in the neighboring districts of Namwala and Kalomo. It has
its own Hospital-Affiliated Health Center, which serves as
the outpatient department. Malaria transmission has traditionally been hyper-endemic in the MMH catchment area,
which covers approximately 160,000 persons.12
The second hospital, Livingstone General Hospital
(LGH), is located in Livingstone District and serves an
urban/semi-urban catchment population estimated to be
240,335.13 As a government second-level general hospital,
LGH is a referral facility for the six surrounding districtlevel hospitals and a direct referral hospital for 19 primary
health centers (urban and rural) in Livingstone District and
17 RHCs in Kazungula District. Although LGH does not have
an affiliated outpatient health center, patients can seek care
from LGH on an outpatient basis by paying a bypass fee.
Malaria control in relevant catchment areas. In 2003,
the Zambian government announced the introduction of
a revised malaria treatment policy using ACTs, moreeffective anti-malarial drugs than chloroquine and sulfadoxinepyrimethamine (SP). Zambia became the first country in
Africa to adopt ACTs, using artemether-lumefantrine as the
national first-line therapy for the treatment of uncomplicated
malaria, and a phased approach. In 2006, purchasing challenges at the central level led to ACT shortages throughout
Zambia, although stocks recovered to adequate levels in
2007 (Thuma P, unpublished data).
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MMH began using ACTs as its first line of treatment soon after the government announced its new policy
(Figure 1). Kalomo District, in MMH’s catchment area,
was among the seven districts that had been first selected to
receive ACTs in early 200314; the ACTs then became available in Choma District in late 2003 and in Namwala District
in late 2004.
In late 2003, MIAM designed a test-and-treat and community education campaign for malaria in a random sample
of villages in the hospital’s catchment area, whereby all positive cases (symptomatic and asymptomatic) were treated with
ACTs. In 2004, this campaign was rolled out and screened
925 persons; this increased to 2,024 persons in 2005 and
3,070 persons in 2006 (Mharakurwa S, unpublished data).
In 2005, the three districts in MMH’s catchment area
received RDTs in line with a new policy decision by the
National Malaria Control Program to roll out RDTs to all
districts to strengthen confirmatory diagnosis of malaria.15
The distribution of ITNs had been gradually scaled up in
Choma District during 2003–2005. In 2007, MIAM participated in the Ministry of Health’s ITN distribution for the
northern part of Choma District, distributing 24,000 ITNs
through eight RHCs surrounding the hospital; this increased
the self-reported rate of use of an ITN in the previous night
to more than 80% in MMH’s catchment area.16 Targeted
IRS was rolled out in Choma District in 2008, but only in
peri-urban areas, which meant that it did not reach MMH’s
catchment area.
At LGH, ACTs were introduced in 2003 (Figure 2); in
Livingstone District, ITN distribution began in 2003 and
continued during the following years (Katebe C, unpublished data). In Kazungula District, although some ITNs
were distributed before 2007, mass distribution began in
2007 (Lubinda M, unpublished data). Targeted IRS began

Figure 1. Malaria interventions in Macha Mission Hospital (MMH), Zambia, catchment area. DhART = dihydroartemisinin; ACT;
artemisinin-based combination therapy; IPTp = intermittent preventive treatment of malaria for pregnant women; MIAM = Malaria Institute
at Macha; ITNs = insecticide-treated nets.
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Figure 2. Malaria interventions in Livingstone General Hospital (LGH), Zambia catchment area. IRS = indoor residual spraying; ITN =
insecticide-treated net; IPTp = intermittent preventive treatment of malaria for pregnant women; ACT = artemisinin-based combination
therapy; CHW = community health workers; RDTs = rapid diagnostic tests.

in 2005 in Livingstone District and in 2004 in Kazungula
District. By 2006, IRS had been significantly scaled-up in
Kazungula District.
In Kazungula District in 2007, the District Medical Office
trained community health workers (CHWs) and RHC staff
in the use of RDTs and community-based treatment with
ACTs based on the concept of home management of
malaria. This training expanded the availability of diagnostic testing and treatment to the community level by including community-based treatment through CHWs (National
Malaria Control Center, unpublished data).
METHODS
Data collection. Our study relied on longitudinal, retrospective, facility-level and patient record data collected
from both hospitals. We obtained aggregate outpatient visit
and inpatient admission data for malaria at MMH from the
hospital’s archived disease aggregation forms and from
previously compiled disease aggregation form data. Similar
data on inpatient and outpatient visits for malaria at LGH
were collected from Livingstone District’s disease database.
Malaria inpatient record data for MMH came from an
electronic database of pediatric malaria patient records
(patients < 6 years of age) covering all admitted pediatric
patients during 2003–2008.† The records included data on
age, sex, length of stay, malaria microscopy results, primary
and secondary discharge diagnosis, malaria treatment, and

†At MMH, the pediatric ward includes patients under 6 and the
adult ward includes patients 6 years and over. At LGH, the pediatric ward includes patients under 5 years, whereas the adult ward
includes patients 5 years and over. From here on, we refer to patients
from MMH as under-6 or 6 years and over, and patients from LGH
as under-5 or 5 years and over.

blood transfusions.‡ The primary and secondary diagnoses
were used to categorize patients by malaria diagnosis (uncomplicated, severe, or complicated).
We also obtained a subset of electronic records that
were available for adult patients (patients ³ 6 years of age).
The data from male malaria patients ³ 6 years of age covered January 2002–April 2007 and May 2008–April 2009.
Female malaria records for patients ³ 6 years of age were
available only for April 2001–September 2002 and for
June 2008–July 2009. The patient record data from MMH
for patients ³ 6 years of age include age, sex, length of
stay, and the physician’s primary diagnosis, but no data on
treatment are available. None of the patient records have
information on diagnostic tests except for the malaria microscopy results for patients < 6 years of age. Therefore, we
assumed that patients received diagnostic testing according
to the hospital’s protocol.
At LGH, malaria patient record data were obtained by
first reviewing paper copies of patient registries to identify
malaria patients. Only a subset of all patient registers was
located for the study period. We searched for patient records
by identified malaria cases; only a non-random subset of

‡Recognized treatment guidelines (WHO) classify malaria based
on symptoms. Severe malaria is used to classify malaria cases with
specified complications such as high parasite levels, severe anemia,
coma and other complications. Malaria without such symptoms
are considered uncomplicated. Because the treatment of malaria
differs depending on the presence of complications, for the purposes
of our costing estimates, it was necessary to distinguish between
malaria cases, which had a complication and malaria cases that were
hospitalized and received treatment beyond ACTs or SP alone but
did not involve these complications. For this paper, uncomplicated
cases (for Macha only) are those that respond to ACTs or SP alone;
severe malaria cases are those that do not respond to ACTs or SP
alone; complicated malaria cases are those with a related complication (anemia and/or cerebral malaria).
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patients < 5 years of age and patients ³ 5 years of age was
found in hospital archives, and this significantly limits the
quality of the available data.§
From the LGH patient records, we obtained data on age,
sex, length of stay, malaria treatment, other drugs provided,
blood transfusions, and, when available, the results of
malaria diagnostic testing. Because not all patient records
included a primary diagnosis, we retroactively assigned a
malaria diagnosis when it was missing, based on consultation
with the hospital’s Senior Resident Medical Officer.¶
We obtained input cost data from the medical supply
order forms from Medical Stores Limited. Except for
ACTs, the cost data were available for only a one-year
period. Thus, we applied a constant price per input over
time for both hospitals.k Because we had yearly price data
for ACTs, we accounted for their decrease in price over time.
At both hospitals, we interviewed nurses, physicians, laboratory technicians, and clinical officers to obtain a listing of
all supplies and drugs used to treat and diagnose malaria,
as well as costs related to procedures such as blood transfusions. To account for labor-related costs, we also relied
on the hospital’s malaria treatment protocols (available at
MMH), and used staff interviews to obtain estimates of
time spent on care of malaria patients by task. Because official malaria treatment guidelines were not available at LGH,
we interviewed physicians responsible for patient care to
obtain a description of malaria treatment protocol by severity
and complication. For both hospitals, aggregate hospital
expenditure data were obtained from the hospitals’ MidTerm Expenditure Framework Reports, as well as from
human resources, laboratory, pharmacy, and stores records.
Data analysis. Our study is structured as two case studies,
rather than a comparative assessment, given differences
in the availability and quality of data from each hospital.
We use a pre-post approach comparing our outcomes of
interest during the period before scale-up of malaria control interventions in the relevant catchment areas with
those same outcomes during the period immediately after
scale-up. The period selected for each hospital was based

§For 2005, 2006, 2007, and 2008, the total number of malaria
records found was 133, 106, 90, and 124, respectively. Of these
malaria records, the number of records for patients < 5 years of
age in each of these years was 55, 21, 8, and 2, respectively, and
the number of records for patients ³ 5 years of age was 78, 85, 82,
and 122, respectively. The non-random sample reflects the fact
that the retrieved patient records were not obtained based on a
random selection from the entire set of malaria patient records
because only a subset of these records were located. Because the
sample is not random, it could be biased, meaning it is not representative of the entire population of malaria patients.
¶The categorization of each patient by malaria diagnosis was
based on the available data in the patient record, which included
malaria drugs, other drugs, and blood transfusions. However, there
were no data in patient records on hemoglobin count (to determine
severity of anemia) or malaria diagnosis (whether confirmed or
unconfirmed). There were also no data on whether the patient was
in coma, which may bias downwards the proportion of cerebral
malaria cases because only the cases with convulsions were identified as cerebral malaria cases.
kThe cost data collected on RDTs include two types of available
RDTs: Plasmodium falciparum and SD Bioline, which cost $0.16
and $0.41, respectively. Because there is uncertainty about the
availability over time of these two RDTs, and how often each was
used relative to the other, we used the average of both prices.
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on the timing of the malaria control scale-up and data availability. For MMH, we used 2003 as the pre-period, and 2004
through 2008 as the post period. For LGH, we used 2005
and 2006 as the pre-period, and 2007 and 2008 for the post
period. The differences in data availability at both hospitals
required us to apply, when necessary, different analytical
approaches for each hospital.
Our main outcomes of interest were: 1) number of outpatient malaria visits at the hospitals’ affiliated health center,
2) number of inpatient malaria admissions relative to admissions for other diseases, 3) average financial cost to the hospital of an inpatient malaria admission (by complication/year/
age group), and 4) total hospital expenditures on malaria
admissions relative to overall hospital expenditures by year.
In comparing malaria-related admissions and outpatient
visits over time, we also included the total number of
admissions/visits (for other diseases and conditions) during
the pre-post period to determine whether the proportion of
admissions/visits for malaria changed over time relative to
other diseases. Monthly data for MMH were available for
both outpatient visits and inpatient admissions, enabling us
to impute missing values.** At LGH, no imputation could
be performed because monthly data were not available.
Therefore, outpatient visits and inpatient admissions may be
under-estimated in cases where monthly values are missing.
Our costing methods used a financial costing approach
from the perspective of the hospital. We did not consider
the costs to patients. We included only the direct costs of
malaria patients’ testing and treatment as well as overhead
costs, and exclude the opportunity cost of inputs such
as capital and infrastructure. Overhead costs include nonclinical staff costs, staff training, maintenance of buildings
and equipment, transportation, office supplies, electricity,
water, internet, and hospital project-related costs. In addition, although hospital input costs, such as RDTs, may be
partly subsidized by the government or donors, our estimates
represent the costs incurred by the hospital and do not
reflect the total costs incurred by the government or donors.
At both facilities, we estimated the cost of inpatient
malaria admissions, disaggregating our estimates by year
according to patient age group and malaria diagnosis.†† For
MMH, we included uncomplicated malaria as a category for
inpatient admissions for patients < 6 years of age because
some young patients with uncomplicated malaria may be
hospitalized for better patient management (either because
of patient presentation, such as vomiting, or because of distance between hospital and home).

**Only three months of inpatient admissions for malaria were
missing at Macha (2003–2008). We imputed these missing months
by using the percentage change in admissions between two consecutive non-missing months, and evaluated this change at the midpoint between the two months, to avoid estimating an undefined
value when the first month was equal to zero.
††Malaria diagnoses include uncomplicated malaria (only for
patients < 6 years of age at MMH), severe malaria, malaria with
anemia, malaria with severe anemia, cerebral malaria, cerebral
malaria with anemia, and cerebral malaria with severe anemia.
Although there are other complications that may occur as a result
of malaria, such as acute renal failure and acute pulmonary edema,
these are not included in our primary categorizations because
they are relatively rare compared to these primary complications
associated with severe malaria.
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Our costing method relied on available information from
patient records regarding treatment received. Using patient
record data enabled us to reflect differences between official clinical guidelines and treatment practices because of
availability of resources or a physician’s need to make clinical decisions while awaiting diagnostic results. For MMH,
patient records were available for all malaria patients < 6 years
of age during the study period; complete data on malaria
treatment per case were also available. Because malaria
records for patients ³ 6 years of age at MMH lacked data
on malaria treatment or blood transfusions, we use the ratio
of malaria treatments provided to patients < 6 years of age,
by year and by complication, to estimate malaria treatment
of patients ³ 6 years of age, adjusting for adult dosing. By
accounting for differences in malaria treatment by year, we
include the transition from SP to ACTs. For LGH, the
malaria patient records for patients < 5 years of age and
those ³ 5 years of age included malaria treatment data by
year and by complication.
The costing approach also reflects differences between
the two facilities in the malaria drugs available and provided
(Supplemental Table 1A). For example, at LGH, there was
a higher rate of use of intravenous quinine, administered
for more days, but at MMH, there was a higher rate of
use of dihydroartemisinin (a monotherapy artesunate) for a
subset of patients, in combination with other standard drugs
(such as SP or quinine). The cost estimates for drugs include
malaria drugs and other drugs, such as anti-convulsants
and antibiotics, provided to treat malaria complications.
We excluded the cost of drugs used to treat diagnoses not
related to malaria.
Diagnostic testing by malaria complication differed
between both facilities (Supplemental Table 1B) and is
reflected in the cost estimates based on the treatment protocol at each facility. The MMH used microscopy for all
inpatient admissions through 2006. The RDTs were introduced at MMH for outpatient visits starting in 2007, before
which approximately 50% of outpatient malaria cases were
diagnosed based on symptoms; by 2010, RDTs were used
routinely for outpatient visits, although for inpatient admissions, they were used only when microscopy was unavailable, such as on weekends.‡‡ Our costing assumptions
presume that all MMH malaria admissions received microscopy and, beginning in 2007, only a subset first received an
RDT.§§ All inpatient malaria admissions are assumed to
have received microscopy at LGH during the study period.
At both facilities, the cost of staff time per patient was
estimated using the time per task related to patient diagno-

‡‡Although microscopy was used throughout this time period to confirm inpatient admissions, microscopy was used in only approximately
50% of outpatient cases before 2007, meaning that the remaining
cases were diagnosed based on symptoms. Before 2010, malaria diagnosis for outpatient visits was often based on symptoms if microscopy was not available, or if doing microscopy would delay care.
§§At LGH, RDTs were not introduced until 2012 for use in outpatient visits. The RDTs were not introduced at LGH until 2012
because the initial policy was such that any hospital, especially
level 2 and upwards, with microscopy capabilities was not supplied
with RDT kits. Only in 2012 did it become possible for LGH to
stock and use them, after complaints from delays in providing
appropriate treatment given the poor courier system from the
medical/pediatrics outpatient wards and the laboratory.

sis, treatment, and care, as reported through staff interviews.
Yearly staff salaries are used to obtain the cost of staff
per minute. The only cost input affected by the length of stay
is the cost of staff time per day spent monitoring patients and
administering drugs. For MMH patients < 6 years of age, we
used individual-level length of stay data for patients < 6 years
of age because all of their patient records were available.
For MMH patients ³ 6 years of age and for all patients at
LGH, we used the average length of stay by complication
and by age group but did not disaggregate by year.
To estimate total hospital expenditures on malaria admissions by year and by age group, we used the ratio of malaria
complications by year/age group, our estimates of average costs
by complication/year/age, and the total number of admissions
for malaria by year/age. We then compared total spending on
malaria admissions relative to overall hospital expenditures
(for direct expenses and overhead, excluding capital and
building costs) to estimate the proportion of total hospital
resources devoted to malaria inpatient admissions each year.
All cost estimates (including staff costs) represent real
U.S. dollars in 2008. Costs are calculated in real terms
(adjusting for inflation) using 2008 Kwacha and then converted into U.S. dollars by using the average exchange rate
across all months in 2008 to account for currency fluctuations.
This study was exempted from institutional review board
review by the Abt Associates Institutional Review Board.
The study received ethical approval from Eres Converge
in Lusaka, Zambia and from the Macha Research Trust
Institutional Research Board.
RESULTS
Results for MMH. The comparison over time of outpatient visits and inpatient admissions for malaria at MMH
showed a substantial decrease in total malaria cases from
2003 through 2008 (Figure 3).
Outpatient visits and inpatient admissions for malaria at
MMH represent a decreasing share of total visits during
this period. The percentage of under-5 outpatient visits
for malaria decreased from 42% in 2003 to 11% in 2005,
increased to 21% in 2006, and reached a low of 4% in 2008
(Figure 3). At MMH, the Health Management Information
System (HMIS) disease aggregation forms report data by
persons < 5 years of age and those ³ 5 years of age, and the
patient ward data divide patients as pediatric (< 6 years of
age) and adult (³ 6 years of age). A similar trend was
observed for the proportion of outpatient malaria visits for
patients ³ 5 years of age and for the proportion of inpatient
admissions for malaria for patients < 5 years of age and
those ³ 5 years of age. Inpatient admissions for patients
< 5 years of age made up 20% of all inpatient admissions
in 2003 compared with 1% by 2008.
The analysis of the case-mixture of patients by disease
at MMH over the study period showed that total admissions followed a similar trend to admissions for malaria
(Figure 4). In 2003, the number of admissions for patients
< 5 years of age was 3,170. Total admissions decreased
until 2006, when there was an increase in total admissions,
similar to malaria admissions. After 2006, total admissions
continued to decrease to their lowest level by 2008. The
analysis is restricted to the top 12 conditions for simplicity.
The change over time in total admissions is not solely

COSTS ASSOCIATED WITH SCALE-UP OF MALARIA CONTROL, ZAMBIA
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Figure 3. Outpatient visits and inpatient admissions for malaria at Macha Mission Hospital (MMH), Zambia.
Note: The percentages represent the number of outpatient malaria visits out of total outpatient visits (by age group) at MMH and the
number of inpatient malaria admissions (by age group) out of total admissions for all ages at MMH. Since data on inpatient admissions at
MMH could not be disaggregated by age group, these percentages are likely to be under-estimated.

explained by changes in malaria admissions because admissions for other diseases (such as diarrhea, anemia, and
malnutrition) also decrease during this period.
For patients ³ 5 years of age at MMH, total admissions followed a similar trend over time during 2003–2005.
Although total admissions increased in 2006, they continued

to increase in 2007 but decreased by 2008. Similarly, the
trend in admissions for malaria does not completely explain
the change in total admissions given that admissions for
other diseases increased during this period, e.g., for acquired
immunodeficiency syndrome (AIDS), tuberculosis (TB), and
pregnancy complications.

Figure 4. Admissions of patients < 5 years of age, by disease, Macha Mission Hospital (MMH), Zambia. AIDS = acquired immunodeficiency syndrome; TB = tuberculosis.
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Table 1
Costs estimates (per admission) for inpatient malaria admissions (patients < 6 years of age), Macha Mission Hospital, Zambia
Year
Malaria diagnosis

2003

2004

2005

2006

2007

2008

Uncomplicated malaria
Severe malaria
Malaria with anemia
Malaria with severe anemia
Cerebral malaria
Cerebral malaria with moderate anemia
Cerebral malaria with severe anemia

$32.40
$40.12
$37.49
$76.50
$52.36
$58.24
$96.64

$32.65
$38.15
$31.03
$73.61
$38.58
$34.51
$90.50

$20.26
$39.84
$39.16
$82.13
$43.09
$112.87
$89.56

$53.08
$47.54
$35.46
$62.62
$44.97
$26.99
$90.29

$35.69
$43.70
$26.53
$58.42
$47.92
$43.19
$83.54

$66.63
$64.70
$39.62
$85.78
$41.84
$117.06
$65.18

Summary data (Supplemental Table 2A) from the MMH
patient medical records show that for patients < 6 years of
age, the percentage of admissions for uncomplicated malaria
of total malaria admissions increases during the study period,
compared with admissions for severe malaria or malaria with
complications. As explained above, the patient record data
for data are divided by pediatric ward (persons < 6 years of
age) and adult ward (persons ³ 6 years of age).
In 2003, 24% of malaria admissions for patients < 6 years
of age were for uncomplicated malaria compared with 77%
by 2008. By 2008, 8% of malaria admissions were for severe
malaria without complications, and malaria with moderate
or severe anemia accounted for 9% of malaria admissions
for patients < 6 years of age, cerebral malaria accounted for
3%, and cerebral malaria with anemia accounted for 2%.
The average length of stay of malaria admissions for patients
< 6 years of age increased from 4.5 days in 2003 to 9.3 days by
2008. In addition, the case-fatality rate for malaria admissions in patients < 6 years of age was 4.5% in 2003 compared with 15.5% in 2008. Nonetheless, the absolute number
of deaths had substantially decreased over this period. Data
from patients ³ 6 years of age showed that the rate of
malaria admissions for severe malaria was higher in 2007 than
in 2003 (comparing only male patient data) and the casefatality rate decreased. The data for 2003–2007 represent only
male malaria admissions for patients ³ 6 years of age because
patient records for female patients ³ 6 years of age were not
available for these years. There may be differences in complications rates for malaria by sex, which why we do not use
2008 as a comparison year.
Using the patient record data, we found that the cost
estimates for malaria admissions were disaggregated by
malaria complication for patients < 6 years of age (Table 1).
For patients < 6 years of age, the average cost of malaria
admissions increased with the complexity of the malaria
diagnosis; in 2003, the average cost of an uncomplicated
malaria admission was $32 compared with $77 for malaria
with severe anemia. Similarly, in 2003, cerebral malaria
costs on average were $52, but cerebral malaria with severe

anemia costs were $97. The main differences in average
cost over time are primarily driven by the differences in
length of stay by year and by complications. For example,
the average length of stay for an uncomplicated malaria
patient in was 5.2 days in 2003 compared with 9.8 days in
2008. Finally, the reason that cerebral malaria with moderate anemia in 2005 appears as an outlier in terms of costs
is that of the three patients in this category in that year,
one received six blood transfusions during the stay, and
they are relatively costly. Although outlier data for length
of stay were truncated, values that represent plausible
lengths of stays were kept in the data.
The total average costs were estimated based on the average costs per input category (such as drugs and staff); in
results not included in Table 1, the average cost of malaria
drugs for uncomplicated malaria admissions among patients
< 6 years of age increased from $0.36 in 2003 to $0.75 in
2004, reflecting the introduction of ACTs. Despite subsequent decreases in the unit price of ACTs, the average
cost of anti-malarial drugs further increased by 2008
($0.85) because all patients were receiving ACTs by that
year. Similar per-patient costs were estimated for malaria
admissions among patients ³ 6 years of age, by complication and by year (Supplemental Table 3A). Using the
average cost per patient by complication and by year, we
estimated total spending by year on malaria admissions
(Table 2). In 2003, total spending on inpatient malaria
admissions at MMH was estimated to be $86,018, which
accounts for 10.8% of total hospital expenditures in that
year. In comparison, total spending for malaria patient
admissions in 2008 decreased to $4,631 and accounted for
0.4% of total hospital expenditures.
Results for LGH. A comparison over time of outpatient
visits and inpatient admissions for malaria showed that total
visits for malaria were relatively similar from 2005 through
2007, but there was a substantial decrease in malaria cases
by 2008 (Figure 5). These trends were consistent for
patients < 5 years of age and those ³ 5 years of age, as well
as for outpatient malaria visits and inpatient admissions.

Table 2
Summary of yearly costs for all malaria admissions at Macha Mission Hospital, Zambia*
Year
Variable

2003

2004

2005

2006

2007

2008

Total inpatient malaria costs (patients < 6 years of age)
Total inpatient malaria costs (patients ³ 6 years of age)
Total costs for malaria admissions
Total reported hospital expenditures (real USD 2008)
Proportion of hospital expenditures on malaria admissions

$65,336
$20,681
$86,018
$796,776
10.80%

$16,897
$5,230
$22,127
$579,701
3.82%

$4,349
$2,602
$6,951
$680,881
1.02%

$25,893
$10,593
$36,486
$716,064
5.10%

$12,819
$5,517
$18,336
$802,949
2.28%

$3,187
$1,443
$4,631
$1,272,415
0.36%

*USD = U.S. dollars.
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Figure 5. Outpatient visits and inpatient admissions for malaria at Livingstone General Hospital (LGH), Zambia.
Note: The percentages represent the number of outpatient malaria visits out of total outpatient visits (by age group) at LGH and the number
of inpatient malaria admissions out of total admissions at LGH (by age group).

As a percentage of total hospital visits, the largest change
over time occurred for malaria patients < 5 years of age,
who accounted for 27% of outpatient visits in 2007 compared with 5% in 2008. The percentage of inpatient malaria
admissions for patients < 5 years of age relative to total
admissions for patients < 5 years of age decreased from
18% in 2005 to 2% in 2008 (Figure 5).
The analysis of the case mixture of admissions over time
at LGH shows that although admissions for malaria
decreased over the study period, there was an increase in
total admissions of patients < 5 years of age from 2005
through 2007, after which they subsequently decreased by
2008 (Figure 6). The increase in total admissions was attributed to increases in admissions for anemia, AIDS, trauma,
pneumonia, TB, and other major diseases and conditions.
There was also a less pronounced decrease in admissions
for diseases such as perinatal conditions, diarrhea, and
malnutrition. Among patients ³ 5 years of age, total admissions during 2005–2008 increased. Given that admissions
for malaria decreased during this period, the increase in
total admissions during 2005–2008 for patients ³ 5 years
of age was driven by an increase in admissions for diseases,
including trauma, TB, delivery complications, and cardiovascular diseases.
Summary characteristics (Supplemental Table 4A) for the
sample of patient records showed that 53% of malaria
admissions for patients < 5 years of age in 2005 were for
severe malaria. The rest of the patients represented admissions for malaria with complications; this proportion was
relatively constant across the years. For patients ³ 5 years

of age, the proportion of admissions for severe malaria
(compared with malaria with complications) was 60% in
2005 and 78% in 2008. The average length of stay of
malaria admissions among patients < 5 years of age was
4.5 days in 2005 compared with 7 days in 2008. In comparison, the average length of stay for malaria admissions
among patients ³ 5 years of age was 3.7 days in 2005 and
2.7 days in 2008.¶¶
The average cost estimates for admissions of malaria
patients < 5 years of age were relatively similar by year
and by complication (Table 3). There were certain outlier
costs, such as in 2005, when cerebral malaria with anemia
and malaria with severe anemia cost on average more than
severe malaria. However, these cost differences do not exist
for the other years. In addition, cerebral malaria appeared
to cost on average more in 2006 and 2007, relative to the
other years. The main cost driver explaining these differences between years and by complication is the higher
proportion of patients who received intravenous quinine
in certain years. At LGH, the use of intravenous quinine,
including supplies such as saline solution, is relatively costly
because of the length of time that patients remain receive it.

¶¶There is some uncertainty about the number of cases that we
categorized as cerebral malaria cases. The patient records did not
have information on whether the patient was in a coma. Therefore,
it is likely that certain cerebral malaria cases with coma are underreported. Cases with seizures were identified and included as cerebral malaria cases.
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Figure 6. Admissions of patients < 5 years of age, by disease, Livingstone General Hospital (LGH), Zambia. AIDS = acquired immunodeficiency syndrome; TB = tuberculosis.

At LGH, patients who receive intravenous quinine receive
the treatment for 6 days (1 day with the loading dose and
5 follow-up days). As part of the treatment, they are also
given saline twice per day for the length of the intravenous
quinine treatment, and this saline is the main cost driver
for the supplies associated with intravenous quinine.
Similar costs were estimated for patients ³ 5 years of age
at LGH (Supplemental Table 5A). On average, the costs
of treating malaria patients ³ 5 years of age was lower compared with patients < 5 years of age. This difference in average
cost was largely driven by the shorter average lengths of stay.
Finally, using the proportion of patients by complication,
year, and age group and the average cost of each complication (by age group and year), we estimated that total spending on malaria admissions at LGH in 2005 was $50,008,
which represented 2% of total hospital expenditures in that
year (Table 4). By 2008, total spending on malaria admissions at LGH decreased to $9,346, which represented 0.3%
of the hospital total expenditures in that year.
DISCUSSION
At both hospitals, the substantial decrease in outpatient
visits and inpatient admissions for malaria during the study
period coincides with implementation of malaria control
Table 3
Costs estimates (per admission) for inpatient malaria admissions
(patients < 5 years of age), Livingstone General Hospital, Zambia
Year
Malaria diagnosis

2005

2006

2007

2008

Severe malaria
Malaria with anemia
Malaria with severe anemia
Cerebral malaria
Cerebral malaria with
moderate anemia

$60.69
$61.34
$80.53
$65.27
$81.87

$61.21
$60.62
$61.56
$78.06
$62.91

$62.17
$62.19
$63.35
$75.41
$64.64

$62.52
$62.25
$63.41
$62.39
$64.98

interventions in catchment areas. For MMH, the decrease
in malaria admissions from 2003 through 2005 was consistent with introduction of ACTs as the first line of treatment
for uncomplicated malaria and implementation of the testand-treat campaign. The subsequent increase in malaria admissions in 2006 was consistent with the shortage of ACTs that
was experienced countrywide during that year, which may
have led patients to either bypass the health center or
receive hospital referrals because of treatment shortages at
the lower levels of care.17 In addition, ACT shortages caused
recourse to less-effective monotherapy, primarily SP, to which
resistance was prevalent, potentially leading to ineffective
treatments that resulted in hospitalization.18
After 2006, malaria admissions decreased to their lowest
level in 2008, which coincides with improvement in the
availability of ACTs as a first-line treatment, the distribution of ITNs in the catchment area, and the high rates of
ITN ownership province wide.
At LGH, the substantial decrease in outpatient visits and
inpatient admissions for malaria occurred during 2007–2008.
These decreases were consistent with introduction of the
first mass-distribution of ITNs in Kazungula district in
2007 and implementation of CHW use of RDTs and ACTs
provided through community-based treatment. Although
both interventions were implemented in 2007, their effects
may have been delayed, depending on the timing of the
roll-out of these interventions relative to the rainy season.
In addition, although IRS in Kazungula began in 2004, it
was substantially scaled-up by 2007. Earlier malaria control
interventions, including ITN distribution in Livingstone District in 2003, occurred before the period (2005) when data
were available for this study. However, it is not clear why
there was no change in the trend before 2007, given that
IRS was rolled out in Livingstone District in 2005. It may
be that malaria admissions and visits were even higher
before 2005 and the trend from 2005 through 2007 already
captured the effect of this IRS roll-out.
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Table 4
Summary of yearly costs for all malaria admissions at Livingstone General Hospital, Zambia*
Year
Variable

2005

2006

2007

2008

Total inpatient malaria costs (patients < 5 years of age)
Total inpatient malaria costs (patients ³ 5 years of age)
Total costs for malaria admissions
Total reported hospital expenditures (real USD 2008)
Proportion of hospital expenditures on malaria admissions

$24,401
$25,607
$50,008
$2,637,976
1.90%

$27,741
$39,305
$67,047
$2,071,604
3.24%

$19,262
$33,359
$52,621
$2,262,162
2.33%

$2,308
$7,038
$9,346
$2,949,503
0.32%

*USD = U.S. dollars.

Given the reductions in inpatient admissions for malaria
at both hospitals, we inferred the potential implications for
the availability of resources for patients with other conditions. At MMH, the decrease in total hospital admissions
over time was not entirely explained by the decrease in
malaria admissions. However, the simultaneous decrease in
admissions for diseases such as diarrhea, anemia, and malnutrition could have been influenced by the reduction in
malaria prevalence if, for example, malaria affects an individual’s susceptibility to other conditions, or if persons were
classified by malaria-related condition such as anemia, rather
than being classified as having malaria directly. In contrast,
admissions for some diseases, such as AIDS among patients
³ 5 years, increased.
At LGH, the trend in total admissions increased from
2005 through 2007, and admissions for malaria decreased.
The increase in total admissions among patients < 5 years
of age was attributed to increases in admissions for other
diseases including anemia, AIDS, trauma, pneumonia, and
TB. Among patients ³ 5 years of age, the increase in admissions was attributed to admissions for trauma, TB, delivery
complications, and cardiovascular diseases. For both hospitals, malaria admissions accounted for a smaller share of
total admissions by the end of the relevant study periods.
In hospitals where resources are scarce, such as when there
is full bed occupancy, the decreased burden of malaria
admissions on the health facility could potentially free up
resources for other patients and improve the quality of care
through reduced congestion in wards.
Our cost estimates provide evidence of the financial
resources used by each hospital for malaria admissions.
Our results highlight that at both facilities, there is a reduction in the proportion of financial resources used to treat
malaria admissions. At MMH, this ratio decreased falls
from 11% of total hospital spending in 2003 to < 1% by
2008 (Table 2). At LGH, although the difference over time
in the proportion is much smaller (2% in 2005 and 0.3% in
2008; Table 4), the relative change represented an 81%
reduction in hospital spending on malaria admissions in
2008 compared with 2005. As a comparison, spending on
malaria admissions in 2005 at MMH made up 1% of total
hospital spending. The similar proportion in spending in
2005 potentially suggests that the malaria burden at MMH
may have been higher to begin with, thereby explaining the
larger change over time in resources devoted to malaria
admissions compared with LGH. Although the reduction
in the proportion of spending on malaria admissions, relative to total hospital spending, could be a function of other
factors (such as an increase in total hospital spending),
these observed reductions are largely driven by the reduc-

tion in total spending on malaria admissions (resulting from
decreases in malaria admissions).
Compared with 2003, when total spending on malaria
admissions at MMH was $86,018, total spending on malaria
admissions in 2004 was $22,127, generating cost savings of
$63,891 for that year. The cumulative cost savings from
2004 through 2008 is estimated to be $341,559. The cumulative cost savings is calculated as the sum of the difference
between the costs of malaria admissions in each year
compared to the costs of malaria admissions in 2003 for
Macha and 2005 for Livingstone.
At LGH, total malaria spending in 2005 was $50,008,
compared with $9,346 by 2008. The cumulative cost savings
from 2006 through 2008 was $21,010. However, this comparison underestimates cost savings because malaria admissions
did not substantially decrease until 2008. The estimated
cost savings from 2007 through 2008 were much larger
($43,275). Overall, these results provide evidence of the
financial resources that could subsequently be made available for treating other diseases and conditions, as malaria
admissions decrease.
Our study also provides a more nuanced view of the
financial resources hospitals use when treating malaria,
because our methods rely on data from patient records.
The cost estimates reflect clinical practices at each hospital
rather than the treatment protocol. Particularly in contexts with shortages of resources, there may be differences
between these factors. One example is the difference in
use of drugs, such as antibiotics and intravenous quinine,
between LGH and MMH. At LGH, 90% of malaria
admissions for patients < 5 years of age were provided
with antibiotics (which are relatively expensive given the
length of time they are administered). At MMH, antibiotics
are prescribed only to malaria patients with no other
comorbidities in cases of confirmed or suspected sepsis. We
suggest follow-up research to compare differences between
actual treatment provided by hospitals to malaria patients
and national treatment protocols and reasons for such differences. Such analyses would help highlight areas for cost
savings and efficiency gains in the health system, as well as
resource constraints, training and supervision needs. This
research would also help identify where guidelines may need
adjusting or when gui1delines may be absent, and isolate
other factors affecting quality of care.
Other factors that also influence resources used for
treating malaria admissions include differences in characteristics of the patient population. For example, LGH is a
referral hospital and may tend to receive relatively sicker
patients than do lower-level hospitals. Although we have
case-fatality estimates for malaria patients at both hospitals
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based on patient records, meaningful comparisons cannot
be made because of the small sample size of records for
LGH, which might significantly skew these outcomes.
Nonetheless, patient record data from MMH provide suggestive evidence of changes over time in patient
characteristics for malaria admissions, which will affect average costs of these cases and total costs of malaria admissions
overall. One important cost driver is patient’s length of stay
in a hospital At MMH, the average length of stay increased
over time, as did the case-fatality rate for malaria admissions. At the same time, the proportion of patients being
seen for uncomplicated malaria increased over time, relative
to the proportion of malaria patients with severe malaria or
complications. This finding may be the result of patients
being admitted for other conditions as their primary diagnosis, given that the analysis did not distinguish between
patients’ primary and secondary diagnoses. In addition,
anecdotal evidence suggests that physicians may have been
more likely to admit patients with uncomplicated malaria
cases as malaria admissions became rarer because physicians
had less frequent exposure to severe malaria cases. Because
our data were obtained from patient records, we were able
to show how average costs for malaria admissions change
over time in relation to changes in patient characteristics
and provider behaviors in terms of treatment decisions and
admission patterns.
Limitations. The primary limitation of this study was data
quality at LGH, where only a subset of all malaria patient
records could be located. The LGH sample is therefore
small and may be unrepresentative of the entire population
of malaria admissions at that hospital. Because the analysis
is presented by year, malaria complication, and age group,
some of these categories have few observations. This situation creates large variations in costs within different categories, and these variations do not necessarily represent
real cost differences. However, it was necessary to use the
same methods across both hospitals for consistency.
Another limitation was the absence of coverage data
for most of the malaria control interventions; without these
data, it is difficult to provide causal inference on the impact
of malaria control on hospital admissions and costs.
Follow-up research using coverage data could provide further substantive evidence of the association between the
scale-up of malaria control and its impact at the health
facility level. A recent analysis of HMIS data in Zambia
showed a significant decrease in the absolute number of
facility-confirmed malaria cases and a marked decrease
in case-fatality rates in patients < 5 years of age, which
is concurrent with introduction of malaria control interventions during 2007–2008.19 Although our analysis did
not show direct causality caused by data limitations, it
appeared consistent with trends observed by Chanda
and others.18,19
We were also not able to control for concurrent interventions that might have affected health-seeking behavior
related to malaria during the study period. One factor
related to the introduction of RDTs; diagnosis based
on clinical presentation has been shown to over-estimate
the number of malaria cases, compared with the use of
RDTs.20 At MMH, part of the decrease in outpatient
malaria visits during 2007–2008 could be attributed to the
introduction of RDTs. However, the decrease in malaria

inpatient admissions during this same period would not be
explained by RDTs because these cases are confirmed by
microscopy. Outpatient visits for malaria at MMH during
2003–2006 are likely over-estimated given the higher tendency to diagnose malaria based on symptoms only.
The data for outpatient visits at LGH do not distinguish
between confirmed malaria and clinical malaria, making it
difficult to determine whether the number of malaria visits
might be over-estimated. Given that all inpatient admissions were diagnosed based on microscopy, the introduction
of RDTs in 2012 cannot explain the trends in malaria
admissions during the study period. Nonetheless, anecdotal
evidence suggests that even when the MPS was negative
for inpatient admissions but symptoms were suggestive of
malaria, a malaria diagnosis would be documented. Based
on data obtained from HMIS for 2009–2011 for malaria
outpatient visits show that, on average, 81% of cases were
diagnosed clinically and were not confirmed through
microscopy, suggesting the potential for over-estimates of
malaria diagnosis for both outpatient and inpatient malaria
cases during the entire study period. However, given that
there were no changes in diagnosis practice during this
same period, this finding would not explain the decrease
in malaria cases during 2007–2008 at LGH.
Other factors may have also changed during the study
period and may have affected malaria visits and admissions. Data on outpatient malaria visits at the health centers in the relevant catchment area showed similar trends
to those for malaria visits and admissions at both hospitals.
These similar trends at the health center level provide
suggestive evidence that other factors, within the catchment
areas, are less likely to explain the changes in malaria
admissions at each hospital.
One important potential confounder was the widespread
and severe drought during the 2004–2005 rainy season
in Zambia. A study in two villages in the Macha region
demonstrated that transmission was reduced virtually to
zero as a result of this drought and that transmission
rebounded during the 2005–2006 rainy season when the rains
increased.19 This drought could partly explain the substantial
decrease in outpatient visits and inpatient admissions for
malaria observed for 2005. However, it would not explain
the reductions in outpatient visits and inpatient admissions
for malaria observed during the 2003–2004 rainy season. In
addition, because the data include later years during which
there were also substantial decreases in outpatient visits
and inpatient admissions for malaria (in 2007 and 2008)
but no drought, our conclusions regarding the effect of
malaria control scale-up at the facility level still hold.
Conclusion. In summary, we provide strong evidence that
the decrease in inpatient admissions and outpatient visits for
malaria at both hospitals occurred at the same time that the
malaria control interventions were implemented and scaled
up in the catchment areas for both facilities. The particular
type of malaria control intervention, such as the test-andtreat campaign in MMH’s catchment area, may not be representative of malaria control strategies in other settings.
Nonetheless, their effectiveness in controlling malaria and
the subsequent changes in health-seeking behavior at the
hospital provide important evidence to inform how the
health system at the facility level is affected by the scale-up
of malaria control. In addition, the findings identify the
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magnitude of financial resources devoted to malaria admissions at each hospital and show, over time, the extent to which
malaria accounts for less of the financial costs at the facility.
Further research is warranted to replicate these findings
in other settings, such as in different geographic locations.
Our study also highlights the need for coverage data on
malaria control strategies, data that distinguish between
clinical and confirmed malaria cases, and, overall, higher
quality HMIS data to better understand the impact of
malaria control at the health facility level. As countries
scale up and maintain coverage of malaria control interventions, there are benefits to the health facility, with resources
that could be made available for other purposes, potentially
including under-resourced diseases or conditions.
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